Jefferies initiated coverage of enGene (ENGN) with a Buy rating and $28 price target The company is running a pivotal high-risk non-muscle invasive bladder cancer study with a key update in the second half of 2026, the analyst tells investors in a research note. The firm says enGene’s interim data are competitive versus cretostimogene with a “clear differentiator” being the company’s practice-friendly profile. enGene’s detalimogene is “positioned to stand out,” contends Jefferies.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ENGN:
- enGene Secures Expanded $125 Million Debt Facility to Advance Bladder Cancer Gene Therapy
- 3 ‘Strong Buy’ Stocks to Buy Today,12/26/2025, According to Top Analysts
- 3 ‘Strong Buy’ Stocks to Buy Today,12/24/2025, According to Top Analysts
- Reaffirming Buy on enGene: Strengthened LEGEND Phase 2 Data, Robust Cash Runway to 2028, and Path to 2026 BLA for Detalimogene
- enGene (ENGN): Advancing Detalimogene Toward Commercialization in NMIBC with Practical Competitive Edge Justifies Buy Rating and $25 Target